8-K: Tivic Health Exercises Option for Neutropenia Indication, Issues Shares

Tivic Health Systems exercises its option to acquire the exclusive worldwide license for the Neutropenia indication of Entolimod and issues shares to Statera Biopharma and Avenue Venture Opportunities Fund.

Summary

• Tivic Health Systems, Inc. has exercised its exclusive option to acquire the worldwide license for the Neutropenia indication of Entolimod from Statera Biopharma, Inc.
• This is under the existing License Agreement between the two companies.
• Tivic Health paid a license fee of $1,500,000 to Statera, consisting of $300,000 in cash and $1,200,000 in stock.
• As consideration for exercising the Neutropenia Exclusive Option and accelerating the first milestone payment, Tivic Health issued 55,704 shares of common stock and 131.1267 shares of Series A Preferred Stock to Statera and Avenue Venture Opportunities Fund.
• Tivic Health is now obligated to develop and commercialize the licensed products related to the Neutropenia indication at its own cost and expense, including meeting milestones and paying milestone payments.
• Milestone payments for Neutropenia include $500,000 for filing an IND and initiating a Phase 2 clinical study, $750,000 for Phase III completion, and $1,500,000 for filing a BLA with the FDA and achieving FDA approval.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is expanding its pipeline, it is also taking on additional financial obligations and diluting shareholders.

Positives

• Tivic Health expands its pipeline by acquiring rights to the Neutropenia indication.
• The company has the option to accelerate milestone payments, potentially speeding up development.
• The company has secured an exclusive worldwide license for the Neutropenia indication.

Negatives

• Tivic Health is now obligated to fund the development and commercialization of the Neutropenia indication.
• The company is obligated to make milestone payments upon achieving specific milestones.
• The company issued shares, which may dilute existing shareholders.

Risks

• The development and commercialization of the Neutropenia indication may not be successful.
• Tivic Health may not be able to meet the required milestones.
• The company may need to raise additional capital to fund the development and commercialization of the Neutropenia indication.

Future Outlook

Tivic Health will develop and commercialize the licensed products related to the Neutropenia indication and meet the milestones outlined in the License Agreement.

Industry Context

The development of treatments for Neutropenia is an area of unmet medical need, and Tivic Health's acquisition of the rights to Entolimod for this indication could position them as a player in this market.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards without knowing the specifics of Entolimod's efficacy and safety profile.
• Other companies developing treatments for Neutropenia include Amgen (Neupogen, Neulasta) and Sandoz (biosimilars).
• The milestone payments are typical for this stage of drug development.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees will be involved in the development and commercialization of the Neutropenia indication.
• Patients with Neutropenia may benefit from the development of a new treatment option.

Next Steps

• Tivic Health will file an IND and initiate a Phase 2 clinical study for Neutropenia.
• The company will continue to develop and commercialize the licensed products related to the Neutropenia indication.
• Tivic Health will need to meet the milestones outlined in the License Agreement.

Key Dates

Keywords

Neutropenia, Entolimod, Tivic Health, Statera Biopharma, License Agreement, Milestone Payments, Exclusive Option, Shares, FDA, Clinical Study